This study is about the efficacy of antibiotics and their combinations with adjuvants which are usually prescribed to treat infections and in the treatment of the severe infections called sepsis, so as to improve the quality of treatment in future.

The efficacy of meropenem with disodium edetate (EDTA) and ceftriaxone with sulbactam and EDTA compared to meropenem alone in the treatment of sepsis. - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055896

Enrollment

Registered

2023-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere

Interventions

Intervention1: meropenem with EDTA: intravenous infusion of injection meropenem 1 gram with EDTA 37mg over 3 hours for 10 - 14 days Intervention2: ceftriaxone with sulbactum and EDTA: intravenous infu

Eligibility

Inclusion criteria

Inclusion criteria: BMI Patients with Sepsis or high suspicion of sepsis

Exclusion criteria

Exclusion criteria: Refuse to participate, withdraw of consent during study time. Age 80yrs Pregnancy, palliative care patients, Severe oliguric AKI at presentation or AKI on DAY 1 or Day 2 of ICU stay. BMI >30

Design outcomes

Primary

Measure	Time frame
compare Risk adjusted mortality rateTimepoint: at 28 days after admission	—

Secondary

Measure	Time frame
The secondary objectives will be the number of ventilator days, length of stay in ICU (meet criteria of readiness to shift to room), the incidence of AKI, VAP, CRBSI, CAUTI, Hypocalcemia, & resistance pattern in cultures.Timepoint: 90 days	—

Countries

India

Contacts

Public ContactRajeshbabu VV

care hospital

reachgpvn@gmail.com94946594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026